Health and Healthcare
Savient's New Gout Treatment Hits Targets (SVNT)
Published:
Last Updated:
Savient Pharmaceuticals Inc. (NASDAQ: SVNT) is seeing its shares surging in pre-market trading. The company showed statistically significant positive results for the Puricase Phase III study in treatment-failure of gout patients. Puricase’s 8mg dosage administered by a two-hour intravenous infusion every two weeks or every four weeks met Savient’s primary efficacy endpoint.
Savient also said it plans to file for approval with the FDA in 2008 based on the positive results from these Phase III trials. If you will recall, this was Jim Cramer’s #1 SPECULATIVE STOCK FOR 2007.
Shares closed yesterday at $14.46, and the 52-week trading range had been $10.58 to $15.75. It now looks like it is trading at a new all-time high of $20.95 in pre-market activity.
Jon C. Ogg
December 13, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
